Pharmaceutical Executive Digest:
Having trouble viewing this e-mail? Click here.

 
You are subscribed to %%list.name%% as %%emailaddr%%.
Click here to unsubscribe or edit your member profile.

Pharmaceutical Executive Europe  E-News
 
 
 
 
 
 

You can now follow us on Twitter at Twitter.com/pharmexecdigi
 
Survey
We asked 40 pharma leaders, to which of the following areas have you made changes to meet the challenge of demonstrating value?

Business model 22%
R&D strategy 22%
Commercial Strategy 22%
All of the above 34%

Talk to us:
editor@pharmexeceurope.com

Advertise with us: jgray@advanstar.com


14 February, 2012
In this Issue
Sales Force Survey 2012: Too Much Business as Usual?
In the global battle for market share, the ability to adapt and mobilize your human assets around a responsive commercial model is a key variable of success. More...
Is It Time to Appoint a 'Chief Patient Officer'?
Sarah Krug argues that it could be time for your company to create a new C-suite position designed to build trust... More...
Fighting Tropical Disease: Now It's a Common Cause
David Torstensson of Pugatch Consilium considers what the London Declaration on Neglected Tropical Diseases reveals about the research and development efforts into this field... More...
GSK Upbeat on 2011 Performance
Check out our short video blog... More...
Global Transparency Reporting Congress — London 2012
Register now for CBI's Global Transparency Reporting Congress, to be held in London 28–29 February 2012, and save £152! More...
Also in this issue…
Shrinking Economy Hits California Biosector
Saving the Next Generation of Regulatory Scientists
Humira: Pharm Exec's Brand of the Year
Case Study
Reducing outsourcing costs and cycle-times
Discover how a biotech saved $600,000 on a Phase II contract, compressed the contracting cycle-time from three months to two weeks, and formed a more constructive and collaborative working relationship with their CRO.
Download the case study today

Event Profile
Pharma Regulatory Policy Exchange
May 7-8, 2012
Washington, D.C.
USA
Prepare for a new wave of legislative and regulatory policies that will shape the life sciences industry for years to come. Learn best practices on how the shifting regulatory and policy landscape will affect the biopharma industry going forward with Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Eisai, Eli Lilly and Company, EMD Serono, Merck, Novartis and Shire Pharmaceuticals!
Register by March 10th at http://www.cbinet.com/policyexchange and save $300 with priority code: QSS925.

 
You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.

To ensure delivery to your inbox, please add us to your address book. If you need help doing this, click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 1-866-529-2922 at any time, or fax us at 1-218-740-6417. Outside the U.S., please phone 1-218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.